If Squalamine far surpasses all other AMD drugs in efficacy, then patients will of course go to the clinic as often as necessary to get treated. But what if Squalamine’s efficacy turns out to be on a par with, for example, Lucentis? Then a dosing regimen that is two-to-four-times as frequent as Lucentis’ schedule might be a significant impediment to Squalamine’s sales uptake.
Market Data 
Markets 
AI
